Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypo-Combi Trial
NCT05003752Phase 2Active, not recruiting
- Start
- Aug 2021
- Primary completion
- Dec 2022
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in prostate adenocarcinoma. Primary endpoint: Rate of acute and early late genitourinary, gastrointestinal and sexual toxicity up to 2 years. Started Aug 2021; status: active, not recruiting.
02
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT05003752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05003752.